Johanna Bendell, Susanna V. Ulahannan, Marianna Koczywas, Julie Brahmer, Anna Capasso, S. Gail Eckhardt, Michael S. Gordon, Caroline Mccoach, Misako Nagasaka, Kimmie Ng, Jose Pacheco, Jonathan W. Riess, Alexander I Spira, Conor Steuer; Richa Dua, Suman Chittivelu, Serena Masciari, Zhengping
Related News
Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2 Inhibitor, at the ...
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium ......
Business Wire 2020-10-22Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 22, 2020-- , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today...
The Marshall News Messenger
2020-10-22
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
PDF Version Preliminary Clinical Activity and Safety Profile Support Advancingto Dose ExpansioninMultiple Tumor Types Recommended Phase 2 Dose Determination Ongoing...
Public Technologies 2020-10-24Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
October 24, 2020 Early Dose-Escalation Data Demonstrate Proof of Mechanism and Support Ongoing Development of SY-5609 for Difficult-to-Treat Cancers On Track to Report...
Public Technologies 2020-10-24Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 ...
SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target...
Tyler Morning Telegraph
2020-10-22
Turning Point Therapeutics Presents Initial Clinical Data�From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor ...
SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target...
Nasdaq Globe Newswire 2020-10-24Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
PDF Version Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
Public Technologies 2020-10-22